FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-02-27

Price

$14.37

+0.28%

Score6.2Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.5xvs 20d avg

Analysis

FOLD is currently trading as a merger arbitrage play following its December 2025 agreement to be acquired by BioMarin (BMRN) for $14.50 per share in cash. The 'Steady Climb' and 'Quiet Storm' signals are structural artifacts of the price drifting toward the deal price as the Q2 2026 closing date approaches. In a Risk-Off regime with falling yields (10y at 3.96%), FOLD acts as a defensive 'cash substitute,' offering a ~0.9% nominal spread (approx. 3-4% annualized) with low correlation to the broader tech sell-off.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

**Thesis:** Pure merger arbitrage. Upside is capped at $14.50 (deal price); current price $14.37 reflects time-value and slight regulatory risk.
**Macro Fit:** As yields drop, the fixed arbitrage spread becomes more attractive relative to treasuries, supporting the 'Quiet Storm' accumulation.
**Risk:** Deal breakage (regulatory/antitrust) would likely re-rate stock significantly lower (pre-deal range ~$10-$11).

← Back to 2026-02-27 View Full FOLD History →Yahoo Finance &nearr;